Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow... small world, huh? Well, I hope Mead's dream will be realized - to benefit her and everyone else. Thanks for making the personal contact. The anonymous message board is a little impersonal for some occasions sometimes.
Miss Theresa,
I, too, send my sincere condolences on the loss of Glen. I occasionally corresponded with him by email about common interests and he seemed like such a genuine, caring man. He had great hopes for the future - in both his health and the stocks he believed in, I'm sure trusting that the financial future of his family would be rewarded.
As far as this stock, it has been a waiting game. Not knowing what he held exactly, Glen's motto was always "Long and strong" - wait for the technology to materialize. There is a bit of a carrot and stick syndrome with Lifeline, where they continue to promise that the product will be out near-term, but we still are holding our breath around here.
I would say follow your heart. If you decide to sell off the holdings, you might want to do it in metered bits. If you want to take a chance, you'll know by the large account balance that something has finally happened. The name of the product is the iT-bra by Cyrcadia Health, which is for breast cancer detection.
Once again, my heart goes out to you. Glen/Mead had much respect from many here on IHub and, I believe, from all who knew him. Take care!
Financials filed, as usually is mid-May. Not sure why OTC Markets had LLBO as lacking info but it's there in a timely fashion:
https://backend.otcmarkets.com/otcapi/company/financial-report/220477/content
https://backend.otcmarkets.com/otcapi/company/financial-report/220476/content
Didn't scour the report but I did see "no dilution" for the quarter and end of 2018, and stats of 34% and 41% share of Cyrcadia on the different reports.
PS: Mead! Hope you are recovering. Haven't checked IHub regularly as no news or action on stock lately. Plus... I also had two surgeries for detached retina the last month and haven't been on the computer or reading with my one good eye! ;) Take care and keep the faith!!
This was just the annual update released a month ago and on OTC Markets News since 2/19/19. Not that it doesn't bear repeating and a good reminder that there are things forthcoming in the next couple months. We just wouldn't want to give the typical naysayers bait to accuse anyone of false hype on old news. If it is encouraging to re-read, by all means - everyone should refresh their eyes.
Oh, not the "News" section but the "Investors" one. There's nothing too exciting to see but it just looks different - or different information, anyway.
I've also noticed (I think) that, even though Cyrcadia Health's website continues to say "being revised", there are changes in parts you can still access in a back door kind of way, I guess. Not sure if that's because it's not a secure website (https:) or what. And I don't remember what was originally, or lastly, in the "Investors" section, but there is different information in the tabs now. http://cyrcadiahealth.com/investors/
Does anyone else remember or have a record of what it used to say?
Maybe it shows that it's difficult to move from patent to market. There could be tens of thousands, if not hundreds of thousands, of patents that never go anywhere. And we know Lifeline has been at this since the 1990's with the octopus contraption. We know the Mexican kid basically ripped off the idea that had already been out there for quite a while. But no one has made the magical leap to verified acceptance and sales yet, even though people are more than ready to accept the product. I think whoever has the solid manufacturing, network and proof of concept will be the winner - and I think Lifeline/Cyrcadia is years ahead. They just need to execute before the exponential leap to the next technology makes it obsolete! :)
I hear you, I understand. If we talk delays, we can talk decades. But in the previous years, we could say either it was easier to scam people or it was easier for the status quo (be it the oil industry or the medical industry) to block newer alternatives. Now, not as much. Time and place.
I believe the SOLOs shuffle had more to do with the mastascope and ovascope but I don't know - maybe all three. I still see two sides - good/evil - that could explain the current state of affairs with the iT-bra delays. I'm still choosing to believe that it's more a matter of time and place, as opposed to blatant manipulation. At this particular place and time, I just can't see truly intelligent people and prestigious companies entangling themselves with a bit player scam. They have as much access to see the history. A.I. and digital health is no longer futuristic and unattainable, but here and now - and Asia/China will be the Silicon Valley of its growth. My two cents.
No specific mention of Cyrcadia, but relatable (from Bayer's G4A):
https://g4a.health/article/defining-engagement-in-an-age-of-patient-monitoring-and-data-collection
Let's hope updates across the board(s) - and across the world!
Hey! How about this?
Monday, January 21 is like the "1" month; 2+1 = 3; therefore tomorrow will be 13. We'll get there somehow!
Meeters met and tweeted:
https://twitter.com/RobRoyea?lang=en
https://twitter.com/HealthEugene?lang=en
Here's another good read on the topic with a familiar name:
https://www.symposium.org/magazine/%E2%80%9Chow-are-you-feeling-today-human
We should also have some new news or update next week, I hope - maybe it could come from the source instead of from our own digging!
Rob Royea re-tweeted Eugene Borukhovich's message about the O2O Conference on 21 January 2019 in Hong Kong, where he will be a keynote speaker (https://twitter.com/robroyea?lang=en&lang=en). This is the same conference both Rob and Chris Bailey spoke at last year and also coincides with Eugene Borukhovich's invitation to meet up-and-coming digital health people in Hong Kong January 19 to 22. Expecting Rob will be one of those he meets and hoping for some kind of news or update from that soon!
Tic, toc, tic...
Quote from an article about soon-to-be-visiting-China-meeting-with-digital-health-start-ups Eugene Borukhovich:
https://www.accenture.com/us-en/insight-perspectives-life-sciences-health-startups
Even short of a buy-out, partnering or interest from a name like Bayer will be very positive for Cyrcadia, et al.
That looks interesting, Confirm - and father to two gr8 girls. Dad's always looking forward to protecting their daughters, he being someone in a pivotal position. I believe Rob's retweet was the first step in requesting a meeting.
And speaking of dads... HAPPY BIRTHDAY, CONFIRM & FATHER! Big day on the 13th. In about 15 minutes, it will be the 14th in Hong Kong but another 8 hours or so, the start of Monday business. Let's see if there's any exciting or eventful news for us still on the 13th!
https://presse.ramsaygds.fr/file/99360/Rapport-annuel-2017-Ramsay-Health-Care.pdf
We look forward to welcoming a new
director to the Board – Dr Claudia Süssmuth
Dyckerhoff PhD – who has extensive global
healthcare experience across Europe, Asia
and the USA. Dr Süssmuth Dyckerhoff is
an external senior advisor with McKinsey
& Company, and has led McKinsey’s Asia
wide Health Systems and Services Sector
where she supported healthcare companies
as well as governments after transferring
to China. She is a director on the boards of
Hoffmann La Roche, Clariant and the med
tech start-up Cyrcadia. Her experience in
healthcare strategy, privatisation of assets
in the health services arena, organisational
redesign, capability building and operational
performance improvement in hospitals, will
be a great addition to the Ramsay Board and
we look forward to her commencement as
a director.
Hey, Bro -
I understand your point. But the video with Rob did clearly say that the launch into the Hong Kong market was first going to be through physician offices until all the regulatory hurdles were cleared. So, depending on if you want to interpret launch to mean "availability" or only "over the counter to the masses" is the issue. Part 2 of the HKIBC interview - around minute 6 or 7 - says that launching through the doctors first will accelerate the public release in late '19 or early '20. That would be like the current FDA clearance here in the U.S. which allows iTbra use through physicians only. Although the U.S. trials were very specific to women already diagnosed by mammogram, I don't know that Hong Kong will be limited that way. After doctors are able to verify and convey positive results, we're still on track with "a launch"... unless January passes without news confirming it.
Mission Accomplished?
Periodic checking on some team members to see what they're up to. Came across Ed Wertzberger's LinkedIn which indicates his role has been (somewhat?) fulfilled (https://www.linkedin.com/in/ed-wertzberger-74897a1):
President, Consumer Division and Board Member
Cyrcadia Health
February 2018 – September 2018 8 months
Reno, Nevada Area
Brought in to establish Consumer Division focus and lead a multi-dimensional team of highly skilled leaders, vendors, partners, and suppliers to bring the product to crowd funding status in less than six months.
? Created five-year revenue generation plan, with three-year potential buy-out opportunity to increase
credibility and value for shareholders.
? Established cash flow management framework for executive leadership team and board to improve
forecasting and business model.
? Negotiated complex contracts and pricing with key vendors and suppliers to meet strategic goals and
fiscal responsibilities.
? Collaborated across two business units to drive go-to-market strategy.
Frankly, I really do wish a larger, established company would buy this out and take the reins of managing it to the proper potential - some cash, some of their stock in exchange, so that the early arrivers can still benefit with its eventual success and growth. A company more reliable in their planning and execution, whose guidance you can take to the bank!
I did take some of my LLBO profits last year and reinvested it in Cisco, who is a responsibly managed company AND pays dividends that you can take to the bank. So, my remaining LLBO shares can hang out through these dips and take the risk. I might have nibbled on the big dip this morning because I believe there will be upside when clinical trials are announced for China. Since that wasn't an official announcement but highly probable, maybe it will be a different type of trial where the plan that was suggested - to roll out the iTbra to clinicians first - will be a dual-edged roll-out/trial. One never does know, does one?
Great article! And 36 states out of 50 already requiring notification of dense breast tissue by the physician - with the legislation flying through unopposed? A physician might want to have something available right there at their office that can run additional scans for just that circumstance. Sounds like a perfect fit. Who wudda thunk it?
A good read never gets old! And thinking of their "small" investment in Cyrcadia, it will be a great building block to their A.I. healthcare interests for more than just that - especially since in the HKIBC interview, Rob Royea mentioned branching out to more detection needs once the iTbra was established.
lol - good find, Sherlock! We'll get to the bottom of this...
In fact, I know Change for a Buck is (or, at least, "was") a direct Cyrcadia investor and I believe Smelly Foot guy. If anyone on here has a stake of that directly and is getting private updates or shareholder meeting invitations, that would be nice to know. Hint, hint...
Hopefully they'll be able to update US. I know we're investors in this company but we're doing all the work on that end. Maybe our just compensation will come in soon.
Like I say - I dunno. Could be the FDA Class I non-filing justification won't require further trials; could be the roll-out in Asia will take care of a lot of evidence; could be the FDA Class II already in hand, with a plan to initially sell to physicians, is why they have personnel in place in the U.S. for that goal. I dunno. Could be pretty much anything. But try to think big.
I certainly could be wrong, and often am, but to have a new U.S. member on the Cyrcadia team with experience in "bringing life-saving technologies to market" should mean they haven't abandoned the U.S. market. I dunno.
New name on the scene - Cyrcadia since January 2019 (might need a sharper profile picture though). More info on the LinkedIn page, including experience and recommendations:
https://www.linkedin.com/in/julia-mills-79b81a7?trk=org-employees_mini-profile_title
Julia Mills
VP Business Development & Physician Liaison at Cyrcadia Health
Raleigh, North Carolina Health, Wellness and Fitness
Current
Cyrcadia Health, JoinTeamLife, The Life Center For Healthy Aging
Previous
Apeiron Center for Human Potential, Muses Labs, OneMedMarket
Education
Eastern Michigan University
Recommendations 12 people have recommended Julia Mills
Summary
Leveraging 20+ years technology education, pharmaceutical & medical sales, marketing and MedTech business development expertise, to bring life-saving technologies to market.
Experience
Cyrcadia Health
VP Business Development & Physician Liaison
Cyrcadia Health
January 2019 – Present 1 month
Reno, Nevada Area
'Breast Wellness Through Early Detection'
Developer of the ITBra™, non-invasive sensor technology, measuring and detecting tissue abnormalities with a focus on dense breast tissue.
Duly noted - and anxiously awaiting the results of your inklings. I always like the number "13" myself. And, in reading Chinese numerology, I see two sides to that story too. I like this one, though ( http://chineseonthego.com/culture/numbers.html ) :
Hey, Bro!
While I'd agree with you that sometimes people are given a date and think it's more monumental than it is - which happened back in August, I think, and a couple other times - one thing that's fairly regular is when the LLBO reports are put out. According to the last few years, we are not due the prior year reports until late March or April, so I don't believe that is what's being referred to now. I don't know what it is that will happen January 13th, but I'm fairly sure it isn't an annual report. What I can figure out, though, is January 13 is a Sunday - and Hong Kong/China is 13 hours ahead of the U.S., meaning our January 13 is their Monday, January 14 most of the day. That's about all I can figure out at the moment.
Right on, bro! :)
Thanks. And to you too. The journey is half the story and usually involves some struggle. May the road rise up to meet you. May the wind always be at your back. May the sun shine warm upon your face, and rains fall soft upon your fields.
LLBO! Yay!
No, I got it. I just said I don't believe that's the peak. But timing is everything. Some people buy on the hype and sell on the news, right? To each their own. I guess it depends on what the news is.
Well, that would be an incomplete math equation in my opinion. If that 2.5% is Asia alone, that is still a very big multiple. And if, as stated, that is the first variable of a much longer calculation that still involves the U.S. and others, there are a lot of (x), (y) and (z)'s before the =. But if this gets rolling and builds a good buy-out price, that will be a lot easier for us to bottom line.